dndn and onc.res.intl.ltd.

Has ACl ever addressed what their involvement is likely to be in this?

After all, if the company is in such good hands then there must be a strategic plan to go forward and create shareholder value.

A single swallow does not make a summer right? Well, nor does a single drug make a company. Take a look at Provenge and DNDN. FDA approval but no insurer will touch it. Could well be the case with ACL now that the competition has got first mover advantage.

If the leadership isn't addressing the strategic issues that blight the fate of this company then anything they say is coming out of their backside.